ERBB2 and breast cancer: 111In[In]-BnDTPA-trastuzumab-NLS Injection prepared from the kits exhibited preserved high affinity specific binding to HER2-positive SK-BR-3 human BC cells (mean ± SD: Ka = 3.6 ± 0.4 × 108 L/mol; Bmax = 1.1 ± 0.1 × 106 sites/cell).